| Literature DB >> 24166461 |
Bojan Jelaković1, Jovan Nikolić2, Zoran Radovanović3, Joelle Nortier4, Jean-Pierre Cosyns5, Arthur P Grollman6, Nikolina Bašić-Jukić1, Mladen Belicza7, Danica Bukvić8, Semra Čavaljuga9, Dubravka Čvorišćec10, Ante Cvitković11, Živka Dika1, Plamen Dimitrov12, Ljubica Đukanović3, Karen Edwards13, Dušan Ferluga14, Ljubica Fuštar-Preradović15, Gheorghe Gluhovschi16, Goran Imamović17, Tratinčica Jakovina15, Petar Kes1, Ninoslav Leko18, Zvonimir Medverec19, Enisa Mesić17, Marica Miletić-Medved11, Frederick Miller20, Nikola Pavlović21, Josip Pasini22, Stjepko Pleština23, Momir Polenaković24, Vladislav Stefanović25, Karla Tomić15, Senaid Trnačević17, Ivana Vuković Lela1, Ranka Štern-Padovan26.
Abstract
Currently used diagnostic criteria in different endemic (Balkan) nephropathy (EN) centers involve different combinations of parameters, various cut-off values and many of them are not in agreement with proposed international guidelines. Leaders of EN centers began to address these problems at scientific meetings, and this paper is the outgrowth of those discussions. The main aim is to provide recommendations for clinical work on current knowledge and expertise. This document is developed for use by general physicians, nephrologists, urologist, public health experts and epidemiologist, and it is hoped that it will be adopted by responsible institutions in countries harboring EN. National medical providers should cover costs of screening and diagnostic procedures and treatment of EN patients with or without upper urothelial cancers.Entities:
Keywords: aristolochic acid nephropathy; consensus statement; diagnostic criteria; endemic nephropathy; upper urothelial cancer
Mesh：
Year: 2013 PMID： 24166461 PMCID： PMC4288114 DOI： 10.1093/ndt/gft384
Source DB: PubMed Journal: Nephrol Dial Transplant ISSN： 0931-0509 Impact factor: 5.992